Intellia Therapeutics Inc (NASDAQ:NTLA) price on Thursday, January 16, fall -2.99% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $9.42.
A look at the stock’s price movement, the close in the last trading session was $9.71, moving within a range at $9.25 and $9.91. The beta value (5-Year monthly) was 1.806. Turning to its 52-week performance, $34.87 and $9.59 were the 52-week high and 52-week low respectively. Overall, NTLA moved -26.98% over the past month.
Intellia Therapeutics Inc’s market cap currently stands at around $959.41 million, with investors looking forward to this quarter’s earnings report slated for in February.
The average forecast suggests up to a 522.52% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 52.11M, representing a 43.64% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that NTLA is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
13 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 13 recommend NTLA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
NTLA’s current price about -18.61% and -30.38% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 26.31, while 7-day volatility ratio is 8.66% and 6.27% in the 30-day chart. Further, Intellia Therapeutics Inc (NTLA) has a beta value of 1.81, and an average true range (ATR) of 0.81. Analysts have given the company’s stock an average 52-week price target of $54, forecast between a low of $18 and high of $60. Looking at the price targets, the low is -91.08% off current price level while to achieve the yearly target high, price needs to move -536.94%. Nonetheless, investors will most likely welcome a -473.25% jump to $54 which is the analysts’ median price.
If we refocus on Intellia Therapeutics Inc (NASDAQ:NTLA), historical trading data shows that trading volumes averaged 3.35 over the past 10 days and 2.85 million over the past 3 months. The company’s latest data on shares outstanding shows there are 101.80 million shares.
The 2.02% of Intellia Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 92.55% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 21.67 million on 2024-12-31, giving us a short ratio of 9.35. The data shows that as of 2024-12-31 short interest in Intellia Therapeutics Inc (NTLA) stood at 2422.9999 of shares outstanding, with shares short rising to 18.91 million registered in 2024-11-29. Current price change has pushed the stock -19.21% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the NTLA stock continues to rise going into the next quarter.
